NZ Lung Cancer Research Review Issue 33
In this issue:
– Sacituzumab tirumotecan vs docetaxel after prior treatment failure
– Sacituzumab govitecan as second-line therapy
– Real-world outcomes of treatment strategies after durvalumab
– Longer-term follow-up of single-agent divarasib
– Systemic anti-cancer treatment in Māori patients
– Incidental findings during LDCT lung cancer screening
– National variation in the treatment of lung cancer in NZ
– Polygenic risk score and disease incidence and mortality
– Age-related survival differences based on real-world data
Expert contributor
Dr Aileen Ludlow
Aileen Ludlow is a medical oncologist at Auckland Public Hospital specialising in the management of Lung and GI cancer. She completed her oncology training in Christchurch before going on to do a research fellowship at the Royal Marsden Hospital in London. She is a principal and sub-investigator on several industry and collaborative group trials. She […]
Expert contributor
Dr Paul Dawkins
Dr Paul Dawkins is a Respiratory Physician at Middlemore Hospital and Honorary Senior Lecturer in Medicine at the University of Auckland. He is clinical lead for lung cancer at Middlemore, and chairs the National Lung Cancer Working Group and Northern Cancer Network lung tumour stream. He is principal and co-investigator for a number of commercial […]
Latest Publications and Videos
Stay up to date with our latest clinical information.
Explore Research Review Publications and Videos
Dive into our publications and videos content from over 50 areas of medicine including Cardiology, Diabetes, Oncology, Haematology and Psychiatry.
Terms and Conditions
Website terms of use
By using our website, you agree to follow these terms and conditions.
Privacy policy
We take your privacy seriously. To understand how we collect, use, and protect your information, please read our Privacy Policy, which is part of these terms.
Copyright and use of website content
The content of our website is protected by copyright, trademarks, and other legal rights. You can: view, download, or print a single copy of content for your personal or professional use.
You cannot: copy, modify, or distribute website content, or use our website content for commercial purposes or in other works without permission.
Links to third-party websites
The Research Review website may link to third-party websites for your convenience. However:
We do not endorse or approve their products, services, or actions.
We are not responsible for their content or how they operate.
There is no formal partnership between us and third parties unless we clearly state otherwise.
Disclaimer and limitation of liability
We do our best to keep the information on our website accurate, but we do not guarantee that it is always correct or up to date.
To the fullest extent allowed by law, we are not responsible for:
Any loss, damage, or costs you may suffer from using (or being unable to use) our website.
Any decisions you make based on the information provided.
Any business losses, such as lost profits, lost data, or business interruptions.
Governing law
These terms are governed by New Zealand law. If there is a dispute, it must be resolved in a New Zealand court.
